Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jul 06, 2022 4:08pm
103 Views
Post# 34806291

RE:RE:RE:RE:Quarterly earnings report

RE:RE:RE:RE:Quarterly earnings report The earnings announcement has not been delayed, only the announcement of which date they will announce earnings on has been seemingly delayed. I am sure there is some way they can appeal to the SEC for a delay in announcing their financial results beyond 7/15 but they would likely have to announce that too and it would have to be a something pretty meaningful to get the SEC to agree. It is definitely curious but it could also just be the new IR officer likes to give one week notice instead of two. 

PWIB123 wrote: I've never really seen a good reason for delaying an earnings announcement.  It makes investors nervous.  But, maybe they've been super pre-occupied with preparing financial scenarios and potential outcomes based on what they think is about to happen from the clinical trials.  Or maybe they're navigating around an uptick in calendar events that is dependent on something specific over the next few days.  They can change the agenda for presentation, but no reason to delay the details for how to access the earnings call and the date and time, especially when you've waited until the last possible day.

bassini wrote: The last four, 2 weeks exactly 




<< Previous
Bullboard Posts
Next >>